[시장보고서]칼슘 채널 차단제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약물 유형별, 용도별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

칼슘 채널 차단제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약물 유형별, 용도별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Calcium Channel Blockers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Type, By Application, By Distribution Channel, By Region & Competition, 2020-2030F

상품코드 : 1703318

리서치사 : TechSci Research

발행일 : 2025년 04월

페이지 정보 : 영문 180 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,279,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,674,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,163,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

칼슘 채널 차단제(CCB) 세계 시장 규모는 2024년 160억 2,000만 달러로 평가되었고, 예측 기간 동안 강력한 성장세를 보이며 2030년까지 연평균 6.20%의 성장률을 보일 것으로 예측됩니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	160억 2,000만 달러
시장 규모 : 2030년	230억 4,000만 달러
CAGR : 2025-2030년	6.20%
급성장 부문	Dihydropyridine (DHP)
최대 시장	북미

이 시장은 심혈관 질환(CVDs)의 유병률 증가, 고혈압 유병률 증가, 노인 인구 증가로 인해 꾸준히 성장하고 있습니다. 고혈압, 협심증, 부정맥 치료에서 중요한 역할을 하고 있으며, 광범위한 심혈관 치료제 중 가장 중요한 위치를 차지하고 있습니다.

시장 확대는 건강 인식 증가, 처방약에 대한 접근성 향상, 제형 기술의 발전으로 인해 더욱 가속화되고 있습니다. 신흥국에서는 정부 지원 의료 프로그램 및 민간 부문의 투자로 인해 고혈압 치료에 대한 환자 접근성이 향상되어 CCB에 대한 수요가 가속화되고 있습니다.

주요 시장 성장 촉진요인

심혈관 질환 부담 증가

주요 시장 이슈

규제 복잡성 및 승인 지연

주요 시장 동향

개인 맞춤형 심혈관 치료로의 전환

시장 규모와 예측
- 금액별
시장 점유율과 예측
- 약제 유형별Dihydropyridine, Phenylalkylamine. Benzothizepine)
- 용도별(협심증, 고혈압, 비대형 심근증, 부정맥, 기타)
- 유통 채널별(온라인 약국, 병원 약국, 소매 약국)
- 지역별
- 기업별(2024년)
시장 맵

제6장 북미의 칼슘 채널 차단제 시장 전망

시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 칼슘 채널 차단제 시장 전망

시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 독일
- 영국
- 이탈리아
- 프랑스
- 스페인

제8장 아시아태평양의 칼슘 채널 차단제 시장 전망

시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 남미의 칼슘 채널 차단제 시장 전망

시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 아르헨티나
- 콜롬비아

제10장 중동 및 아프리카의 칼슘 채널 차단제 시장 전망

시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

최근 동향
제품 출시
인수합병(M&A)

제13장 세계의 칼슘 채널 차단제 시장 : SWOT 분석

제14장 경쟁 구도

Bayer AG
Sanofi Sa
Pfizer Inc
Lupin Pharmaceuticals, Inc.
Searle Ltd
Knoll Pharmaceuticals Co
GlaxoSmithKline Plc.
Aventis Inc
AstraZeneca PLC
Novartis AG.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Calcium Channel Blockers (CCB) Market was valued at USD 16.02 billion in 2024 and is expected to exhibit strong growth over the forecast period, expanding at a CAGR of 6.20% through 2030.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 16.02 Billion
Market Size 2030	USD 23.04 Billion
CAGR 2025-2030	6.20%
Fastest Growing Segment	Dihydropyridine (DHP)
Largest Market	North America

This market is experiencing steady growth, driven by the increasing prevalence of cardiovascular diseases (CVDs), the rising incidence of hypertension, and the expanding geriatric population. Calcium channel blockers play a vital role in the treatment of high blood pressure, angina, and certain cardiac arrhythmias, maintaining their significance within the broader cardiovascular therapeutics landscape.

Market expansion is further supported by growing health awareness, improved access to prescription medications, and advancements in drug formulation technologies. In emerging economies, government-backed healthcare programs and private sector investments are enhancing patient access to hypertension treatments, accelerating demand for CCBs.

Key Market Drivers

Increasing Burden of Cardiovascular Diseases

The growing incidence of cardiovascular diseases is a major factor propelling the calcium channel blockers market. As CVDs remain the leading cause of death globally-responsible for approximately 17.9 million deaths annually-the need for effective treatments, such as calcium channel blockers, continues to rise.

Hypertension, a common risk factor for heart disease, often requires long-term pharmacological management. CCBs are among the most widely prescribed antihypertensive agents due to their proven effectiveness and tolerability. However, public health data reveals gaps in awareness and management: around 46% of adults with hypertension are undiagnosed, only 42% receive treatment, and just 21% achieve adequate control of their condition.

The persistent global rise in CVD cases is driving the need for chronic disease management, resulting in a sustained increase in prescriptions for CCBs. Public health initiatives, awareness campaigns, and improved screening programs are also enabling earlier diagnosis and intervention, thereby contributing to market growth.

Key Market Challenges

Regulatory Complexity and Approval Delays

Pharmaceutical companies operating in the calcium channel blockers market must navigate a complex regulatory landscape. Global and regional regulatory bodies impose stringent requirements to ensure drug safety and efficacy, which can pose significant challenges for market players.

The drug approval process-especially for novel or reformulated therapies-demands extensive clinical trials, long timelines, and substantial financial investment. Any unforeseen safety concerns during development can result in delays or additional regulatory scrutiny.

Furthermore, variability in regulatory guidelines across different geographies necessitates continuous adaptation and compliance efforts, potentially slowing down the pace of innovation and product launches in certain markets.

Key Market Trends

Shift Toward Personalized Cardiovascular Therapies

The rise of personalized medicine is reshaping cardiovascular care, including the administration of calcium channel blockers. Advances in genomics and pharmacogenomics are enabling more tailored treatment strategies, allowing clinicians to select the most appropriate drug and dosage based on a patient's genetic profile.

This individualized approach reduces the likelihood of adverse drug reactions and improves therapeutic outcomes, thereby enhancing both clinical effectiveness and patient satisfaction. As healthcare systems globally move toward precision medicine, the integration of pharmacogenomic insights into cardiovascular treatment regimens is expected to support long-term growth in the calcium channel blockers market.

Key Market Players

Bayer AG
Sanofi Sa
Pfizer Inc
Lupin Pharmaceuticals, Inc.
Searle Ltd
Knoll Pharmaceuticals Co
GlaxoSmithKline Plc.
Aventis Inc
AstraZeneca PLC
Novartis AG

Report Scope:

In this report, the Global Calcium Channel Blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Calcium Channel Blockers Market, By Drug Type:

Dihydropyridine
Phenylalkylamine
Benzothizepine

Calcium Channel Blockers Market, By Application:

Angina
Hypertension
Hypertrophic Cardiomyopathy
Arrhythmia
Others

Calcium Channel Blockers Market, By Distribution Channel:

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Calcium Channel Blockers Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Calcium Channel Blockers Market.

Available Customizations:

Global Calcium Channel Blockers market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Calcium Channel Blockers Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Dihydropyridine, Phenylalkylamine, Benzothizepine)
- 5.2.2. By Application (Angina, Hypertension, Hypertrophic Cardiomyopathy, Arrhythmia, Others)
- 5.2.3. By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Calcium Channel Blockers Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Application
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Calcium Channel Blockers Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Type
    - 6.3.1.2.2. By Application
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Calcium Channel Blockers Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Type
    - 6.3.2.2.2. By Application
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Calcium Channel Blockers Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Type
    - 6.3.3.2.2. By Application
    - 6.3.3.2.3. By Distribution Channel

7. Europe Calcium Channel Blockers Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Application
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Calcium Channel Blockers Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Type
    - 7.3.1.2.2. By Application
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. United Kingdom Calcium Channel Blockers Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Type
    - 7.3.2.2.2. By Application
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. Italy Calcium Channel Blockers Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Type
    - 7.3.3.2.2. By Application
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. France Calcium Channel Blockers Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Type
    - 7.3.4.2.2. By Application
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Calcium Channel Blockers Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Type
    - 7.3.5.2.2. By Application
    - 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Calcium Channel Blockers Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Application
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Calcium Channel Blockers Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Type
    - 8.3.1.2.2. By Application
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Calcium Channel Blockers Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Type
    - 8.3.2.2.2. By Application
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Calcium Channel Blockers Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Type
    - 8.3.3.2.2. By Application
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Calcium Channel Blockers Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Type
    - 8.3.4.2.2. By Application
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Calcium Channel Blockers Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Type
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By Distribution Channel

9. South America Calcium Channel Blockers Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Application
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Calcium Channel Blockers Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Type
    - 9.3.1.2.2. By Application
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Calcium Channel Blockers Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Type
    - 9.3.2.2.2. By Application
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Calcium Channel Blockers Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Type
    - 9.3.3.2.2. By Application
    - 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Calcium Channel Blockers Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Application
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Calcium Channel Blockers Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Type
    - 10.3.1.2.2. By Application
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Calcium Channel Blockers Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Type
    - 10.3.2.2.2. By Application
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Calcium Channel Blockers Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Type
    - 10.3.3.2.2. By Application
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Calcium Channel Blockers Market: SWOT Analysis

14. Competitive Landscape

14.1. Bayer AG
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
14.2. Sanofi Sa
14.3. Pfizer Inc
14.4. Lupin Pharmaceuticals, Inc.
14.5. Searle Ltd
14.6. Knoll Pharmaceuticals Co
14.7. GlaxoSmithKline Plc.
14.8. Aventis Inc
14.9. AstraZeneca PLC
14.10.Novartis AG.